1.20
+0.015(+1.27%)
Currency In USD
| Previous Close | 1.18 |
| Open | 1.19 |
| Day High | 1.27 |
| Day Low | 1.19 |
| 52-Week High | 3.78 |
| 52-Week Low | 1.18 |
| Volume | 1.3M |
| Average Volume | 5.53M |
| Market Cap | 261.35M |
| PE | -0.91 |
| EPS | -1.32 |
| Moving Average 50 Days | 1.64 |
| Moving Average 200 Days | 2.22 |
| Change | 0.02 |
If you invested $1000 in Allogene Therapeutics, Inc. (ALLO) since IPO date, it would be worth $47.8 as of May 09, 2025 at a share price of $1.195. Whereas If you bought $1000 worth of Allogene Therapeutics, Inc. (ALLO) shares 5 years ago, it would be worth $35.78 as of May 09, 2025 at a share price of $1.195.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update
GlobeNewswire Inc.
May 06, 2025 12:30 PM GMT
Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the deve
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire Inc.
Apr 23, 2025 2:12 PM GMT
SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune diseas
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma
GlobeNewswire Inc.
Apr 07, 2025 12:30 PM GMT
Designations Follow Recent Investigational New Drug (IND) Application Clearance for the RESOLUTION Basket Study of ALLO-329 in RheumatologyDual CD19/CD70 CAR T Specifically Designed to Enhance Therapeutic Benefit, Expanding Treatment Potential Across